Despite recent headwinds at present, the stock's outlook remains promising. Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it.

Investing.com -- Eli Lilly and Company (NYSE:LLY) is expanding its neuroscience pipeline through the acquisition of SiteOne Therapeutics in a deal worth up to $1 billion, deepening its bet on non ...

Eli Lilly applied for a tax abatement under the Texas Jobs, Energy, Technology and Innovation program, the Houston Business Journal reported. This initiative—the JETI program—gives a 10-year ...

Eli Lilly has agreed to acquire privately held biopharma company SiteOne Therapeutics, adding a non-opioid-based pain treatment to the big pharma’s pipeline. The sale agreement will see Eli ...

Eli Lilly is expanding its efforts to advance next-generation pain medications. The Big Pharma has penned a deal to acquire SiteOne Therapeutics, primarily for a non-opioid pain asset ready to ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...

Eli Lilly is considering a 236-acre tract of McCord Development’s Generation Park for the manufacturing plant, which would have a direct economic impact worth $2.5B over 10 years, according to ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have they changed positions in the annual IDEA Pharma Innovation Index ...

Eli Lilly (NYSE: LLY) has transformed from a steady pharmaceutical giant into one of Wall Street’s standout growth stories—and it’s not just hype. Powered by blockbuster drugs for diabetes ...

Global pharmaceutical giant Eli Lilly & Co. is considering a $5.9 billion plant in northeast Houston, a potential economic jolt that could accelerate the city’s ambitions to become a national ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are pitted against each other, but only one can be my preferred healthcare stock. Where to invest $1,000 right now? Our analyst team just ...